The mission of the Systems and Computational Biology Core (SCB) is to provide technology resources and support services in systems and computational biology for KCI members, and to promote collaborative research in systems-based oncology across all five Programs. To accomplish this mission, SCB activities are focused in the areas of: 1) workflow planning and experimental design of studies in functional genomics, genetic variation, and cancer systems biology;2) analysis and interpretation of gene expression profiling data (e.g., oncogenomic signatures);3) analysis and modeling of genotype profiling data from both population studies of inherited cancer risk factors and from molecular studies of somatic variation in individual tumors;4) pathway and network modeling of high throughput (""""""""omics"""""""") data for biomarker and drug target discovery;and 5) database management and integration of functional genomics and genotype data for clinical translational oncology (e.g., deployment of NCI caBIG? tools). In particular, SCB activities enable the application of molecular profiling and network modeling approaches to clinical studies ranging from the molecular to the population level. The key service lines for the SCB provide an integrated workflow pipeline for all stages of a systems-based project, from pre-project planning and experimental design through post-experiment data analysis and interpretation. Consultation and user training are key components of SCB's approach to lowering the technology barrier for KCI members who wish to incorporate computational analytics and molecular profiling tools into their research projects.

Public Health Relevance

The Systems and Computational Biology Core provides integrative capabilities that support the translation of results from basic research in cancer biology into practical clinical applications for the diagnosis, prognosis and therapy of cancer as a systemic disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA022453-31
Application #
8411091
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
31
Fiscal Year
2013
Total Cost
$27,938
Indirect Cost
$9,558
Name
Wayne State University
Department
Type
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Herroon, Mackenzie K; Rajagurubandara, Erandi; Diedrich, Jonathan D et al. (2018) Adipocyte-activated oxidative and ER stress pathways promote tumor survival in bone via upregulation of Heme Oxygenase 1 and Survivin. Sci Rep 8:40
Colacino, Justin A; Azizi, Ebrahim; Brooks, Michael D et al. (2018) Heterogeneity of Human Breast Stem and Progenitor Cells as Revealed by Transcriptional Profiling. Stem Cell Reports 10:1596-1609
Blocker, Stephanie J; Shields, Anthony F (2018) Imaging of Nanoparticle Distribution to Assess Treatments That Alter Delivery. Mol Imaging Biol 20:340-351
Guastella, Anthony R; Michelhaugh, Sharon K; Klinger, Neil V et al. (2018) Investigation of the aryl hydrocarbon receptor and the intrinsic tumoral component of the kynurenine pathway of tryptophan metabolism in primary brain tumors. J Neurooncol 139:239-249
Li, Feng; Wang, Yongli; Li, Dapeng et al. (2018) Perspectives on the recent developments with green tea polyphenols in drug discovery. Expert Opin Drug Discov 13:643-660
Ramseyer, Vanesa D; Kimler, Victoria A; Granneman, James G (2018) Vacuolar protein sorting 13C is a novel lipid droplet protein that inhibits lipolysis in brown adipocytes. Mol Metab 7:57-70
Healy, Mark A; Morris, Arden M; Abrahamse, Paul et al. (2018) The accuracy of chemotherapy ascertainment among colorectal cancer patients in the surveillance, epidemiology, and end results registry program. BMC Cancer 18:481
Lacher, Sarah E; Alazizi, Adnan; Wang, Xuting et al. (2018) A hypermorphic antioxidant response element is associated with increased MS4A6A expression and Alzheimer's disease. Redox Biol 14:686-693
Alsaab, Hashem O; Sau, Samaresh; Alzhrani, Rami M et al. (2018) Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages. Biomaterials 183:280-294
Chammaa, May; Malysa, Agnes; Redondo, Carlos et al. (2018) RUMI is a novel negative prognostic marker and therapeutic target in non-small-cell lung cancer. J Cell Physiol 233:9548-9562

Showing the most recent 10 out of 826 publications